Podcasts about CGM

An ICU nurse mom recounts her child's type 1 diabetes DKA diagnosis, winning school CGM monitoring, juggling celiac, and data-driven management with pump/CGM—practical advocacy and tactics parents can replicate. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it.

If you've ever been told your blood sugar is “normal” but you still feel tired, anxious, or can't sleep, this episode is for you.Most people think blood sugar only matters if you have diabetes. But the truth is, your blood sugar impacts every single system in your body... from your energy and sleep to your hormones, cravings, and mood.In this episode, Dani breaks down what blood sugar actually does in the body, the subtle signs it's off (even when your labs look fine), and how modern life, from artificial light to chronic stress, quietly disrupts metabolic health. You'll learn why these issues go far beyond food and how your circadian rhythms, nervous system, digestion, minerals, and mitochondria all play a role in keeping you balanced.You'll walk away understanding why steady blood sugar is foundational for optimal energy, hormones, mood, and long-term health.

In this episode of The Lisa Fischer Said Podcast, Lisa sits down with Kara Collier, registered dietitian and co-founder of Nutrisense, to unpack the truth about metabolic health, insulin resistance, and how continuous glucose monitors (CGMs) are transforming the way we understand our bodies. Kara shares why she left traditional healthcare, the shocking flaws in hospital nutrition, and how real-time data from CGMs empowers behavior change. Whether you're keto, carnivore, plant-based, or just curious, this episode reveals why everyone should wear a CGM at least once. Learn how glucose, insulin, fasting, aging, and hormones all play into the metabolic puzzle—and how Nutrisense is helping thousands take control of their health.     WEBSITE: https://www.karacollier.com/courses/GlucoseAcademy     Nutrisense Page with 33% Discount: https://www.nutrisense.io/marketing/kara-collier     INSTAGRAM: https://www.instagram.com/karacollierrd/     INSTAGRAM:  https://www.instagram.com/nutrisenseio/     FACEBOOK: https://www.facebook.com/nutrisenseio     EPISODE SPONSOR:  https://www.davidsburgers.com/     EPISODE SPONSOR:  https://marlsgate.com     LISA'S LINKS:     Lisa Fischer Said Academy:  https://lisafischersaid.com/academy/     Website:  lisafischersaid.com     For more information on group intermittent fasting  coaching with Lisa, email fasting@lisafischersaid.com     For more information on one-on-one or group health coaching with Lisa, email healthcoaching@lisafischersaid.com     Podcast produced by clantoncreative.com    

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

‣ Book Your COMPLEMENTARY CONSULATION and CALORIE CALCULATION call:- how much & what to eat, exercise & lifestyle recommendations, and specific resources to support you on your journey

The glucose projector is a simple but powerful idea that can only come from someone who lives with type 1 – and sleeps with it! John DeLeo created a digital readout of CGM data that displays the number, and the time, right on the ceiling. John was diagnosed with type 1 in his 40s. We'll talk about his diagnosis, what lead him to this invention, the long road of bringing it to market, and more. Learn more about Glucose Projector here  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Health technologist and science communicator Caitlin Shure (NextSense) joins me to unpack brainwave-measuring earbuds that can both read and change your mental state—starting with sleep.  We dive into why “Gen-1” wearables overwhelm you with charts but don't help you in the moment, how earbud-EEG works (yes, with just three electrodes), the messy truth on EMF fears, and why women—especially moms—need “do-it-for-me” tools, not just dashboards.  This episode is for women—especially busy moms and high-achievers—who want better sleep, calmer days, and science-backed wearables that actually help (not just track). WE TALK ABOUT:  05:00 - Caitlin's origin story: From “not a science person” to neuroscience and science communication 06:20 - Making complex brain science click for everyday life (and why wearables help) 09:55 - Why “one new idea at a time” beats info overload in health education 10:20 - Early neurotech (Muse), then Apple Watch, Oura, CGM—what worked and what didn't 13:20 - Why “wearable must be wearable”: Rings, watches, now earbuds near your brain 14:30 - Starting with sleep: The lowest-hanging lever for memory, mood, and cognition 19:40 - Neurons, synchrony, and how three earbud electrodes capture EEG 24:50 - Women's health use-cases: Pregnancy, postpartum, perimenopause, menopause 29:05 - “Numbers, not judgments”: Why NextSense won't label your sleep ‘good' or ‘bad' 34:30 - What's next: Adaptive Focus and Relaxation sessions (neurofeedback-like audio) 36:30 - Binaural beats: Mixed evidence, likely responders vs non-responders SPONSORS: CaloCurb (get 10% OFF) is my go-to, 100% plant-based alternative to Ozempic—helping you feel full sooner, snack less, and finally trust your body again without needles, drugs, or yo-yo diets. Join me in Costa Rica for Optimize Her, a 5-night luxury women's retreat in Costa Rica with yoga, healing rituals, and biohacking workshops—only 12 spots available. RESOURCES: Trying to conceive? Join my Baby Steps Course to optimize your fertility with biohacking. Free gift: Download my hormone-balancing, fertility-boosting chocolate recipe. Explore my luxury retreats and wellness events for women. Shop my faves: Check out my Amazon storefront for wellness essentials. NextSense website and Instagram Caitlin Shure's website LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

Fit Mother Project Podcast number 166 introduces us to Dr. Melissa Mahan. A 59-year-old grandmother of six, higher-ed leader, and certified professional coach from San Antonio who refused to let family history dictate her future. After a routine checkup in early 2024 revealed an A1C of 6.6 with high cholesterol and blood pressure, she chose a structured, natural path over medication—and found the Fit Mother Project. What followed was a systems-driven transformation built on consistent action, community support, and faith. Within months, Melissa dropped her A1C to ~6.0, normalized her blood pressure, improved her lipid ratios, and lost ~35 pounds—largely by dialing in “protein first,” lifting consistently, and stacking simple habits like morning sunlight walks. She also learned powerful glucose-management strategies through a CGM, discovering how pairing protein/fiber (and avoiding “spike-on-a-spike” combos like soda before pizza) dramatically changed her numbers. Melissa shares the tweaks that mattered (e.g., swapping coconut milk for almond milk in shakes and adding psyllium husk), along with her mantra of the “relentless return”—not perfection, but always coming back to the next right action. She describes how Fit Mother retreats, small-group coaching, and the in-app sisterhood reinforced mindset shifts, helped her navigate menopause challenges, and kept her on track during celebration-heavy seasons. Now, just shy of 60, Melissa is training for senior-level cycling events and planning a 500-mile Camino de Santiago ride in Spain—proof that health creates possibilities. Her challenge to listeners: dare to dream, set a meaningful goal, and finish this year strong.Key Takeaways:A1C 6.6 → ~6.0; BP/lipids trending normal~35 pounds down; energy and mood up“Protein first” meals; stronger satiety, fewer cravingsCGM insights; smarter food order and pairingSkip soda-before-pizza; avoid “spike on a spike”Fiber + protein before carbs; steadier glucoseAlmond milk swap; lower sugar, cleaner shakesPsyllium add-in; soluble fiber, better fullnessMorning sunlight + 20–30 min walk stackStrength training 2–4x/week; progressive overloadPower-meter cycling; targeted endurance gainsRetreats + small groups; consistent accountabilityMenopause-aware tweaks; sleep and stress prioritized“Relentless return” mindset; progress over perfectionBig goal: 500-mile Camino; senior cycling eventsWant To Change Your Life? Check Out Foundations!Foundations is a simple, sustainable, and specific weight loss program designed especially for busy women over 40. With short metabolic training workouts, an easy-to-follow meal plan, and an accountability team there for you every step of the way, Foundations can help you lose weight, regain energy and vitality, and live life to the fullest. Click here to see everything you get when you join FM30X, subscribe to our YouTube Channel, check out our blog, and follow us on Instagram, TikTok, Facebook,

Send us a textHello and welcome to our series “Stay in His Presence.” We are celebrating five years of podcasting by going into our vault, remastering, and rebroadcasting select episodes since June 2020. Last week, we heard the miracle testimony of Michael Dudley and how the Lord healed him from prostate and colon cancer. This week, we will listen to another miracle testimony from Andrea Dudley, his wife, as presented on August 21, 2021. Andrea is the CEO of Habakkuk Publishing, established in 2006. A Christian company that publishes books which inspire, encourage, and impact the lives of people.My name is Stephanie Wright. Let's go to Andrea's encouraging message of Hope Beyond Brokenness.  If you want to contact us or comment on this podcast, please visit our website and select www.cgmissions.com/podcasts, where all episodes are available by category in series format. You can see the most recent video and audio podcasts at: www.youtube.com/@cgmissionsinc then select from the video or podcast"Playlist." CGM is a 501(c)(3) nonprofit. Donations may be made on our website:https://www.cgmissions.com/donate-here-general-and-wecare/

This episode is brought to you by Erin's brand new digital workbook, "Diabetes, Liberated: An Anti-Diet Digital Workbook to Help You Thrive with Type 2 Diabetes." Check it out here: https://www.erinphillipsnutrition.com/workbook and use this link to get 20% off. In this episode, we talk with Beck (they/them), a trans, nonbinary 28-year-old, about their experience navigating a new diabetes diagnosis. A couple of notes: We recorded this back in DECEMBER, and then life got lifey! Better late than never, because we'd hate for you to miss out on this great interview!Erin was sick when we recorded, so apologies for the cough drop sounds for our sensory sensitive friends!In this episode we talk about: How Beck navigated being diagnosed on the young side, and how to process guilt and shame after a diabetes diagnosis.Finding a supportive care team to help you navigate a diabetes diagnosis.Type 2 diabetes vs latent autoimmune diabetes in adults (LADA, sometimes called type 1.5 diabetes), and navigating a shifting diagnosis.Balancing eating disorder recovery with a new diabetes diagnosis.How Beck adjusted their relationship with their CGM (continuous glucose monitor) to use it as a tool for support rather than a tool for punishment.Ways that Beck found helpful to protect themself from weight stigma.Let us know what you think! LINKS:Apply to be on the podcast! Find out more about Kelly hereFind out more about Erin hereDISCLAIMER: We are dietitians and diabetes educators but we are not YOUR dietitians and diabetes educators. The information provided in this podcast is not intended as individualized medical advice, nor is it a substitute for professional medical expertise or treatment. If you have a medical concern, go to your health care provider or seek other professional medical treatment.

Although aging is an inevitable part of life, there are many factors in our control that can help us live long, vibrant lives. Through healthy lifestyle habits, you can actually slow down the biological aging process. Today, you're going to learn the key strategies that can help you reach this goal. On this episode of The Model Health Show, you're going to learn about seven science-backed ways you can slow down your aging process. We're going to cover supplementation, exercise, mindset, and so much more! You're going to hear the latest studies on antiaging, plus tips from some of the top longevity experts. Plus, for each of these tips, I'm going to share some tangible takeaways you can implement immediately. If you want to slow down your aging process and get healthier as you age, this episode is for you. Enjoy!   In this episode you'll discover:  How vitamin D supplementation can reduce telomere shortening. (0:42) What telomeres are. (1:30) The percentage of Americans that are vitamin D deficient. (2:07) Which form of vitamin D to take for antiaging benefits. (3:18) How your sleep quality impacts biological aging. (4:30) The link between sleep and telomeres. (5:32) Why having a consistent sleep schedule is critical for your health. (6:05) The role of sunlight exposure in regulating your circadian rhythm. (13:39) How your gut microbiome can dictate your aging process. (22:45) The importance of eating a diverse range of foods. (26:31) How many servings of fermented foods per week to eat for gut health. (31:09) Why meditation can slow down your aging process. (31:30) The power of having adequate muscle on your body. (38:37) How much tea to drink daily for antiaging effects. (46:08) The incredible role your mind plays in impacting your rate of aging. (49:40) Why being playful can help you live longer. (58:02)  Items mentioned in this episode include:  Levels.link/model  - Join today and get 2 free months with a one-year membership! Piquelife.com/model  - Get exclusive savings on bundles & subscriptions! These 4 Things Are Destroying Your Sleep Quality  - Get better sleep tonight! Eat These Foods to Improve Your Sleep Quality  - Learn about the link between nutrition & sleep! Visualization Secrets Athletes Use  - Hear the interview with Maya Raichoora Seasonal Food Guide  - Find which foods are in season in your area!  Be sure you are subscribed to this podcast to automatically receive your episodes:   Apple Podcasts Spotify Soundcloud Pandora YouTube   This episode of The Model Health Show is brought to you by Levels and Pique. Learn how food affects your health with a continuous glucose monitor (CGM) from Levels. Join today at levels.link/model and get 2 free months with a one-year membership! Go to Piquelife.com/model for exclusive savings on bundles & subscriptions on cutting-edge solutions for your head-to-toe health and beauty transformation. 

B is  the mom of a T1D son who was diagnosed at a 16 months. He is currently 2 and they are about 9 months in to managing diabetes.  Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Type 1 Diabetes Pro Tips - THE PODCAST Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * Omnipod Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

I am delighted to have Jessie Inchauspé, the Glucose Goddess, joining me on the podcast today! Metabolic health is my passion! It is a huge area of focus in my work, and Jessie is truly a gift in the space! She is a rising star author and biochemist with a clear and accessible way of explaining the science behind glucose metabolism.  Jessie joins me today to discuss the impact of glucose metabolism and spikes. We dive into her background and how an accident created her pain-to-purpose story. We discuss the role of continuous glucose monitors and how glucose spikes impact our mitochondria, inflammation, and oxidative stress. We get into glycation and aging, how weight gain is a protective aspect of glucose spikes- or hyperglycemia, and the role of vinegar, movement, and fiber. We also talk about Jessie's new book, her opinions on fasting, and so much more.  I loved interviewing Jessie! Her enthusiasm is contagious, and it is easy to understand why she is such a beloved author in the health and wellness space! IN THIS EPISODE YOU WILL LEARN: Jessie shares how an accident led her to where she is today. Wearing a continuous glucose monitor (CGM) changed everything for Jessie How Jessie developed her simple principles to stabilize glucose levels What is the purpose of glucose in the body? Glucose spikes and our mitochondria Vinegar hack for reducing side effects and symptoms of glucose spikes Being metabolically unhealthy impacts the aging process Benefits of having savory breakfasts and eating vegetables first with every meal Jessie's book, The Glucose Goddess Method How gaining weight protects our bodies from the impact of glucose spikes Walking or moving after meals to balance blood sugar levels Why blood sugar so important Connect with Cynthia Thurlow Follow on X Instagram LinkedIn Check out Cynthia's website Connect with Jessie Inchauspé On her website   Instagram Link for Jessie's new book: Buy a copy of Jessie's book, The Glucose Goddess Method.

Eoin Lacey is a Performance Consultant and Coach who specialises in lifestyle management, health and wellness. We're drowning in health content - who do you trust, and how do you decide what's right for you? Eoin helps us build a practical toolkit for filtering advice, avoiding bias, and making better health decisions you can actually sustain. We cover clickbait vs specificity, evidence vs anecdote, incentives behind online advice, and how to work with your doctor and healthcare professionals using modern tools and simple baselines. We explore a framework to test, review, and adap so you stop outsourcing your health and start steering it.  You'll learn:How to spot advice that's actually relevant to youWhen to involve medical professionals (and why it matters)What “It depends” really means in health and fitnessHow to vet online coaches and spot red/green flagsThe pitfalls of a pill-first approach to careHow to use modern technology and resources alongside your GPA simple “health sat-nav” framework for continuous improvementKey topics: health misinformation, filter health advice, Eoin Lacey, , evidence vs anecdote, bias, wearables, CGM, functional medicine, online coaches, patient advocacy, behaviour change, survivorship bias.Dan: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@thedancampion⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Eoin: @eoinlaceyeducation⁠⁠⁠⁠⁠⁠⁠⁠⁠Get your FREE copy of 20 Books and Podcasts to Change Your Life: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://mailchi.mp/prymal/bookspodcasts⁠⁠⁠⁠⁠Chapters: 0:00:00 - Intro & the problem: info overload in health0:00:08 - Specificity beats clickbait: is this advice for you?  [n=1, relevance] 0:03:41 - Risks of generic plans; steroids/anabolics & N=1 thinking0:05:14 - When to involve medical pros; risk & contraindications0:06:42 - Diet tribes, trends & why “one system” rarely fits0:09:43 - The Lane Norton lesson: science > feelings & “It depends”0:12:14 - Fundamentals don't change: coaching, EQ & service quality0:13:47 - Vulnerability of patients; influencer incentives; bring data0:17:44 - Wearables & meeting your doctor halfway; stop outsourcing0:20:00 - Magic bullets vs sustainable action (with empathy)0:22:57 - Spotting good online coaching: intake, listening, tailoring0:25:00 - Incentives, trust & ‘are they actually listening to you?'0:27:06 - The trust problem post-COVID; healthy skepticism0:30:00 - Use multiple sources; open discussion > ideology0:33:47 - Pill-first limits; functional medicine context0:35:00 - System constraints; lifestyle gaps; collaborate with clinicians0:45:00 - Ideal care pathway vs reality; use tech; reduce overwhelm0:47:48 - Evidence nuance: sample size, population, publication0:49:52 - IF 16:8 origin story; “health sat-nav”: test/review every 2 wks0:55:00 - Building your personal toolkit: baselines, goals, consults1:00:00 - Avoid single-hammer clinics; see the bigger picture1:04:36 - Why online communication misleads; mass plans ≠ you1:10:00 - Algorithm bubbles; when to experiment vs see experts1:12:06 - Resource list idea; align info to your intent/goals1:14:32 - Take what's useful; survivorship bias; don't do everything1:15:17 - Wrap-up, where to reach Eoin

Dr. Hoffman continues his conversation with Jim LaValle, a clinical pharmacist and certified clinical nutritionist, detailing cholesterol's importance and its implications for cardiovascular health. 

September is Cholesterol Education Month. In this episode of Intelligent Medicine, Jim LaValle, a clinical pharmacist and certified clinical nutritionist, details cholesterol's importance and its implications for cardiovascular health. He delves into the nuances of cholesterol types, the historical shifts in perceptions of cholesterol, and how dietary and lifestyle factors influence cholesterol levels and cardiovascular risk. Jim provides expert insights into the roles of LDL and HDL cholesterol, the significance of cholesterol particle size, the impact of carbohydrates on cholesterol, and the benefits of aged garlic extract and other supplements. The conversation emphasizes the importance of comprehensive lipid testing, understanding individual risk factors, and integrating both lifestyle modifications and, when necessary, medications into cardiovascular preventive strategies. The episode concludes with a discussion on the role of health policies and the future of integrative health approaches.

Text us a comment or question!Ever wonder why some foods leave you energized and satisfied while others knock you into a mid-afternoon crash - or make fat loss feel impossible? The answer lies in your blood sugar. And today, we're breaking down how you can finally take control of it. In this episode, I sit down with Kara Collier, co-founder and VP of Health at Nutrisense, to uncover how continuous glucose monitoring (CGMs) and smart lifestyle strategies can help you outsmart stubborn fat, reclaim your energy, and build the lean, strong body you deserve in your 50s, 60s, and beyond. Kara is a Registered Dietitian and one of the leading voices in metabolic health. She's helped over 150,000 people use real-time data and practical tools to create sustainable change - and today, she's sharing those insights with you. What you'll learn in this episode:Why blood sugar spikes and crashes sabotage fat loss, energy, and cravingsThe surprising individuality of how foods affect your glucose (bananas might not be the villain after all!)Simple hacks to keep blood sugar balanced - without giving up your favorite foodsHow stress, sleep, and even the time of day can dramatically impact your glucose responseWhy building muscle is one of the most powerful tools for metabolic healthSupplements and “biohacks” that actually move the needle (and which ones are just pebbles, not boulders) Whether you're struggling with stubborn belly fat, daily energy crashes, or just want to feel younger and more vibrant, this conversation will show you how to finally master The Glucose Game. 

Blood sugar impacts everything—your energy, your sleep, your hormones, your brain, your heart, your thyroid, EVERYTHING. Yet most of us only hear about it in the context of diabetes.  In this episode of the Nutritional Therapy and Wellness Podcast, host, Jamie Belz, and fellow NTP, Ashley Lawrence, open the curtain on the real story behind why blood sugar is often the hidden root behind symptoms like PCOS, anxiety, insomnia, weight struggles, and even long-term risks like cardiovascular disease and Alzheimer's. Ashley—known as the “Blood Sugar Bestie”—shares her personal journey of misdiagnosis, failed quick fixes, and finally discovering that blood sugar balance changes everything. Ashley shares: Her hopeful testimonial story and what she did to “lose her PCOS diagnosis.” Why PCOS is more than “just a hormone disorder”—and how insulin resistance drives much of the imbalance. Why some researchers call Alzheimer's “type 3 diabetes,” and what that really means. How early warning signs like skin tags and darkened patches can show up years before a diagnosis. The reality that blood sugar issues can simmer silently for a decade or more before being labeled diabetes. Practical, joy-filled strategies: pairing carbs with protein, food + mood journaling, hydration hacks, and short-term CGM (Continuous Glucose Monitor) experiments to see what works for your bio-individual body. CLEAN FATS make healthy hormones! (ALL natural fats are healthy - they need to be unadulterated and from clean sources.) This episode isn't about restriction. It's about freedom—learning how simple, everyday choices restore balance, resilience, and joy. Want to go deeper? Continue your journey with these complimentary episodes:: Episode 46: Wellness 101 – A Common Sense Start Episode 28: Blood Sugar 101 — a deeper dive into the basics of glucose, insulin, and cravings. Episode 53: Dr. Lindsey Berkson - Hormones, Libido, and Longevity Connect with Ashley: Instagram: @magicandwellness Website: magicandwellness.com Blood Sugar Bootcamp https://l.bttr.to/sEVmp   Don't forget to subscribe, leave a review, chat with us on Spotify, SHARE, and help change the world!   NOTE: To date, NTA/Jamie are neither affiliated nor receiving compensation of any kind for this or any other product or service featured on The Nutritional Therapy and Wellness Podcast. We simply love connecting good people with other goodness.

durée : 00:02:18 - Le brief éco - Après la mer, la terre… Le géant français du transport maritime de marchandises CMA-CGM continue de tisser sa toile à l'étranger. Après une opération massive aux États-Unis en mars, il rachète le premier opérateur de fret ferroviaire britannique. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

This week on We Are T1D, Mike and Jack tackle the ins and outs of Continuous Glucose Monitors (CGMs) — those little gadgets that keep an eye on your sugars around the clock, often with a bit of drama thrown in for good measure. From the beeping alerts that can wake you at 3 AM to the occasional sensor mishap, they explore how these devices can be both lifesavers and sources of anxiety.Join the duo as they delve into the specifics of CGMs, including their functionality, the different types available in the UK, and why trend arrows are a game changer. They share personal anecdotes, laugh at the chaos that comes with using CGMs, and even take a peek at some hilarious Reddit stories about sensor mishaps.What to Expect:The basics of how CGMs work and why they're essential for Type 1 diabeticsThe difference between the Dexcom and Libre systemsReal-life tales of sensor struggles and triumphsTips for keeping your CGM stuck on, even through showersFuture tech: What could CGMs look like in the coming years?“Without CGMs, diabetes would be 100 times harder.” – MikeConnect with Us:Email: wearet1dpodcast@gmail.comWebsite: www.wearet1d.comInstagram: @t1d_mike & @t1d_jackWhatsApp Community: Join hereExtra Resource:Diabetes UK – Continuous Glucose MonitoringHashtags:#Type1Diabetes #T1DLife #DiabetesPodcast #WeAreT1D #T1DCommunity #CGM #DiabetesTech

Exercise scientist and biohacking pioneer PJ Glassey (founder, X-Gym; author, Cracking Your Calorie Code) joins the Gametime Guru to deliver a playbook for busy athletes: morning hydration that actually absorbs, nutrition on the road for tournaments and travel, and a 21-minute, twice-weekly time-under-tension program that builds precision, coordination, and strength without beating up your joints. We also cover brain-type-based discipline loops, smart use of wearables (Oura, CGM, Apple Watch), and how cold plunge + sauna can boost recovery and mental toughness. Topics: • Hydration: electrolytes, morning rehydration, performance cost of 2–4% dehydration • Travel nutrition: grocery/mini-fridge hacks, protein + veggies first, better fast-food choices • Training: TUT explained, slow-rep precision, nerve training for coordination • Mental performance: identity > motivation, discipline systems, PJ's Brain Type Test • Recovery & tracking: cold plunge/sauna ramping, sleep data that drives changes Website: https://www.xgym.com  Book (Kindle): https://www.amazon.com/Cracking-Your-Calorie-Code-Version-ebook/dp/B09HHGBZZN  Contact: pj@xgym.com Watch on YouTube: https://www.youtube.com/watch?v=5oPsIwosN1U  Subscribe for new episodes weekly and leave a review if this helped your training or coaching.

Send us a textWe are celebrating five years of podcasting in 2025 by going into the archives and remastering the top episodes since June 20, 2020. This is Stephanie, Wright. Thank you for joining us today. Let's get started.Today, we will hear from a man who experienced two miracle healings from colon cancer and prostate cancer. He is the author of the book, "The Miracle Mindset: Cancer is Defeated, I'm Healed." His name is Michael T. Dudley. This is Stephanie Wright, and along with Dr. Apostle Charles G. Wright, we will be listening to Michael Dudley's inspiring interview. If you want to contact us or comment on this podcast, please visit our website and select www.cgmissions.com/podcasts, where all episodes are available by category in series format. You can see the most recent video and audio podcasts at: www.youtube.com/@cgmissionsinc then select from the video or podcast"Playlist." CGM is a 501(c)(3) nonprofit. Donations may be made on our website:https://www.cgmissions.com/donate-here-general-and-wecare/

I am not a doctor. I do not provide medical advice. Always refer to your doctor for authoritative advice. I am a Type 2 Diabetic. I was diagnosed in December 2022. Subsequently, I made numerous Lifestyle changes and by November 2023 my doctor ended my diabetes medication. I continued monitoring my blood glucose levels using a Continuous Blood Glucose Monitor—CGM. By April 2025, my doctor stopped the requirement to wear a CGM. With lifestyle changes and diligence, it was possible to reverse my diabetes naturally. I realized that if I had made the same changes over the previous 25–30 years, preventing my Type 2 Diabetes would have been entirely possible. Diabetes is one of the largest and fastest growing medical illnesses in all parts of the world. Preventing and reversing it when it has manifested is one of the biggest medical and personal challenges we face today.  This is my story, my journey

Prof Shana Kelley is the Neena Schwartz Professor of Chemistry and Biomedical Engineering at Northwestern University and President of the CZI Chicago Biohub, which brings together life scientists at Northwestern, University of Chicago, and U. Illinois Urbana Champaign. Her lab's website provides recent publications in the 3 major areas of biomolecular sensors, rare and single cell analysis, and intracellular molecular delivery.You are undoubtedly familiar with wearable biosensors on the wrist and rings, and continuous glucose monitoring (CGM), all of which can transmit physiologic data in real time to your smartphone. What is different about Prof Kelley's work is the ingenious way of continuously tracking any proteins in our blood via a sensor that could function just like CGM in the future (hair thin sensor applied just below the skin and data relayed to your smartphone). A proof-of-concept paper in Science showed how exquisitely sensitive such a sensor worked to track inflammation markers [interleukin-6 (IL-6) and tumor necrosis factor (TNF)] in the diabetic rat model. As seen. below, just the injection of insulin evoked inflammation, and introduction of lipopolysaccharide (LPS) did so markedly.This capability opens up the potential for monitoring body-wide inflammation in real time, but also extends to many other conditions such as autoimmune diseases, heart failure (e.g. continuous brain natriuetic peptide monitoring), and neurodegenerative diseases (with specific markers of neuroinflammation). This innovation represents a new dimension in individualized (precision) medicine.In our conversation, Shana takes us through the discovery of these unique bimolecular sensors that have no reagents, and use electricity to shake off the protein from DNA strands. And she maps out the path to clinical trials and commercialization in the next couple of years.Thank you Stephen B. Thomas, PhD, Linda Kemp, Lynn L, Pat Mumby PhD, David Hobson, and many others for tuning into my live video with Shana Kelley! Join me for my next live video in the app, along with posts on biomedical news and analysis.***********************************************************************Thanks you for your listening, reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support 47 summer interns in 2025! Get full access to Ground Truths at erictopol.substack.com/subscribe

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Eleven-year-old Toby and his mom share his type 1 diabetes diagnosis, camp adventures, and life with a service dog. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Type 1 Diabetes Pro Tips - THE PODCAST Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * Omnipod Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

My guest is Michael Snyder, PhD, professor of genetics at Stanford and an expert in understanding why people respond differently to various foods, supplements, behavioral and prescription interventions. We discuss how to optimize your health and lifespan according to what type of glucose responder you are, which genes you express, your lifestyle and other factors. Dr. Snyder also explains the key ages when you need to be particularly mindful about following certain health practices. We also discuss how people respond in opposite ways to different fiber types. This episode ought to be of interest and use to anyone seeking to understand their unique biological needs and how to go about meeting those needs. Sponsors AGZ by AG1: https://drinkag1.com/huberman Wealthfront*: https://wealthfront.com/huberman David: https://davidprotein.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman *This experience may not be representative of the experience of other clients of Wealthfront, and there is no guarantee that all clients will have similar experiences. Cash Account is offered by Wealthfront Brokerage LLC, Member FINRA/SIPC. The Annual Percentage Yield (“APY”) on cash deposits as of December 27,‬ 2024, is representative, subject to change, and requires no minimum. Funds in the Cash Account are swept to partner banks where they earn the variable‭ APY. Promo terms and FDIC coverage conditions apply. Same-day withdrawal or instant payment transfers may be limited by destination institutions, daily transaction caps, and by participating entities such as Wells Fargo, the RTP® Network, and FedNow® Service. New Cash Account deposits are subject to a 2-4 day holding period before becoming available for transfer. Timestamps 00:00 Michael Snyder 03:33 Healthy Glucose Range, Continuous Glucose Monitors CGM, Hemoglobin A1c 09:02 Individual Variability & Food Choice, Glucose Spikes & Sleepiness 12:18 Sponsors: AGZ by AG1 & Wealthfront 15:16 Glucose Spikes, Tools: Post-Meal Brisk Walk; Soleus “Push-Ups”; Exercise Snacks 21:06 Glucose Dysregulation, Diabetes & Sub-Phenotypes, Tool: Larger Morning Meal 28:34 Exercise Timing, Muscle Insulin Resistance 30:49 Diabetes Subtyping, Weight, Glucose Control; Incretins 35:41 GLP-1 Agonists, Diabetes, Tool: Muscle Maintenance & Resistance Training 38:40 Metformin, Berberine, Headaches 41:01 GLP-1 Agonists, Cognition, Longevity, Tool: Habits Support Medication; Cycling 47:41 Subcutaneous vs Visceral Fat, Organ Stress 49:10 Sponsors: David & Eight Sleep 51:58 Meal Timing & Sleep, Tools: Post-Dinner Walk, Routines, Bedtime Consistency 57:16 Microbiome, Immune System & Gut; Diet & Individual Variability 1:02:52 Fiber Types, Cholesterol & Glucose, Polyphenols 1:09:50 Food As Medicine; Fiber, Microbiome & Individual Variability; Probiotics 1:18:48 Sponsor: Function 1:20:35 Profiling Healthy Individuals, Genomes, Wearables 1:26:31 Whole-Body MRIs, Nodules, Healthy Baseline, Early Diagnosis 1:34:07 Sensors, CGM, Sleep, Heart Rate Variability HRV, Tools: Mindset Effects, Increase REM 1:39:30 HRV, Sleep, Exercise, Tool: Long Exhales; Next-Day Excitement & Sleep 1:42:48 Organ Aging, “Ageotypes”; Biological Age vs Chronological Age 1:49:41 Longevity, Health Span, Genetics, Blue Zones 1:52:19 Epigenetics, Viral Infection & Disease 1:58:54 ALS, Heritability; Neuroprotection, Nicotine 2:03:47 Air Quality, Allergies, DEET & Pesticides, Inflammation, Mold; Microplastics 2:15:02 Single-Drop Blood Test & Biomarkers, Wearables, Observational Trials 2:20:33 Acupuncture, Blood Pressure 2:26:40 Immersive Events & Mental Health Benefits 2:34:59 Data, Nutrition & Lifestyle; Siloed Health Care vs Personalized Medicine 2:43:06 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Social Media, Neural Network Newsletter Learn more about your ad choices. Visit megaphone.fm/adchoices

Pre-diabetes is no longer a warning sign, it's a national crisis. And the most alarming part? It's not just affecting adults. New data shows that 1 in 3 teens are now considered pre-diabetic. But here's the good news: pre-diabetes is not your fate. It's a call to action.In this eye-opening and empowering episode, Susan and Kate dig deep into the root causes of pre-diabetes in both adults and children, and what you can actually do to prevent or reverse it.They break down:The difference between insulin resistance and pre-diabetesWhat your lab numbers are really telling youHow your genes + lifestyle habits create your current (and future) healthThe silent damage sugar is doing, and how to catch it before it leads to chronic diseaseThe emotional, cultural, and behavioral layers that fuel unhealthy habitsActionable steps to start shifting your family's habits without overwhelm or shameSusan shares powerful insights from working with clients, her personal experience wearing a CGM (continuous glucose monitor), and why stress, not just food, is a major blood sugar disruptor. Kate brings in the emotional and psychological side of habit change, including generational influences and mindset shifts.Whether you're managing your own blood sugar, supporting a child, or trying to break generational cycles of poor health, this episode will leave you empowered, informed, and ready to take action.In this episode:The real cost of pre-diabetes (and why we've normalized it)Why your food choices today shape your health decades from nowWhat labs to ask for, and what numbers are actually optimalWhy sugar is a bigger threat than we thinkThe link between chronic stress, lifestyle, and metabolic dysfunctionHow to create small, sustainable changes that impact your genetic expressionEncouragement and support for families who feel overwhelmed or judgedP.S. Check out our first mini episode coming up on Friday 9/12! RESOURCES:Check out Susan's NEW E-book! Download it FREE here: https://healthyawakening.co/ebook-signupShow notes: https://healthyawakening.co/2025/09/08/episode73Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksConnect with Susan:Check out Susan's NEW E-book! Download it FREE here: https://healthyawakening.co/ebook-signupContact me for your DNA testing or epigenetic coaching! To schedule a FREE Personalized Health Strategy Session, send an email to susan@healthyawakening.coFacebook: https://www.facebook.com/susanrobbinshealthyawakeningInstagram: @susanrobbins_epigeneticcoachSusan's LinkTree: https://linktr.ee/susanrobbinsConnect with Kate King:Kate's Website: https://TheRadiantLifeProject.comKate's Linktree: https://linktr.ee/theradiantlifeprojectP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Można Pięknie Żyć *---Witaj! "Można Pięknie Żyć*" to seria podcastów, w której odkrywamy, jak zmiany w stylu życia mogą poprawić nasze zdrowie metaboliczne. Skupiamy się na Terapeutycznym Ograniczaniu Węglowodanów i jego pozytywnym wpływie na metabolizm oraz ogólne samopoczucie. Pamiętaj, że zdrowie zaczyna się od wiedzy, a my jesteśmy tu, aby dostarczać Ci inspirację i praktyczne wskazówki na drodze do pięknego życia. Zaczynamy!  W tym odcinku dowiesz się, jak **skutecznie komponować dania**, które pomogą wycofać insulinooporność, stan przedcukrzycowy czy nawet cukrzycę typu 2 – bez głodówki, drastycznych wyrzeczeń i nudnych posiłków. Poznaj pięć konkretnych propozycji **niskowęglowodanowych, smacznych i prostych dań**, które zawsze warto mieć w swoim menu oraz listę produktów, które poprawią Twoje zdrowie metaboliczne.Usłyszysz m.in.:Jakie śniadanie naprawdę stabilizuje poziom cukru, a nie powoduje „cukrowej bomby” – bez owsianki, bananów i słodkich płatków.Jak prosto wyliczać **makroskładniki** (białko, węglowodany, tłuszcze) i łączyć produkty tak, aby posiłek wspierał zdrowie i sytość.Menu na cały dzień: jajka, serek wiejski, niskowęglowodanowy chleb, dobrej jakości parówki, mięso, warzywa, zdrowe tłuszcze, boczek, ryby i kreatywne desery na bazie jogurtu greckiego, owoców i czekolady. Jak unikać pułapek żywieniowych i wykorzystywać nowe technologie (aplikacje, czujniki CGM), by kontrolować glukozę po posiłkach.Praktyczne tipy: jakie produkty zawsze warto mieć w lodówce i jak zdrowa kuchnia może zakończyć chorobę metaboliczną.  Odcinek dla każdego, kto chce nie tylko obniżyć cukier, ale też **odzyskać energię, poczuć sytość i cieszyć się zdrowiem** bez rezygnowania z przyjemności jedzenia.  Twój talerz to Twoje lekarstwo – posłuchaj i sprawdź, jak łatwo możesz zmienić swoje życie!=====Dołącz do NIEZALEŻNIE MYŚLĄCEJ i pięknie żyjącej społeczności

Dr. Dominic D'Agostino (@DominicDAgosti2) is a tenured associate professor in the Department of Molecular Pharmacology and Physiology at the University of South Florida Morsani College of Medicine and a Visiting Senior Research Scientist at the Institute for Human and Machine Cognition.This episode is brought to you by: Helix Sleep premium mattresses: https://HelixSleep.com/Tim (27% off all mattress orders)Momentous high-quality creatine: https://livemomentous.com/tim (code TIM for up to 35% off)AG1 all-in-one nutritional supplement: https://DrinkAG1.com/Tim (1-year supply of Vitamin D plus 5 free AG1 travel packs)Timestamps:[00:00:00] Start.[00:14:43] Why I'm interested in ketogenic strategies for neurodegenerative prevention.[00:16:18] Mary and Steve Newport's ketone-linked temporary cognitive improvements.[00:18:18] A mechanisms overview for Alzheimer's/dementia.[00:21:25] The immune system as longevity's "fifth horseman" — and why metabolic control is key.[00:22:04] How to measure ketones and GKI.[00:23:00] Fasting vs. ketogenic diet.[00:24:18] There's nothing fishy about sardine fasting.[00:28:32] My hiatal hernia discovery and increased cancer risk concerns.[00:30:04] HSCRP as a superior biomarker to LDL for cardiovascular risk.[00:31:57] Glucose tolerance testing revelations and CGM importance.[00:31:57] Upgrading the metabolic machinery through keto without getting bored.[00:42:07] What do do if you, like Dom and me, are among the 30% who suffer from cholesterol hyperabsorption.[00:43:42] Dom's day-to-day diet regimen.[00:45:56] How Dom optimizes his aging dogs with ketones, SARMs, and supplements.[00:51:30] Supplementing for sleep disruption while fasting.[00:55:41] Why Dom doesn't have misgivings about melatonin.[00:59:15] Shingles prevention through fasting protocols.[01:00:15] Immune system modulation: Innate vs. adaptive, vegan vs. ketogenic.[01:03:54] Dom at 50-something: Current meal timing and composition.[01:05:57] Blue zone observations: Greek and Sardinian longevity habits.[01:08:16] Ketogenic diet initiation tips: MCT, electrolytes, and fasted cardio.[01:15:18] Ketone metabolic therapy for cancer.[01:18:15] The metabolic psychiatry revolution.[01:22:10] The soothing effects of hyperbaric oxygen and ketosis on seizure sufferers.[01:28:27] Metformin vs. berberine.[01:31:43] The low-dose neuroprotective potential of GLP-1 drugs.[01:34:58] NAD research: MIB-626 and stabilized forms for mitochondrial health.[01:39:48] Idebenone, CoQ10, and the Deanna protocol for ALS.[01:42:05] Dom's supplement short list: CoQ10, creatine, ketones, vitamin D, melatonin.[01:44:43] KetoNutrition.org, Metabolic Health Summit, Audacious Nutrition, veteran-focused research protocols, and other parting thoughts.*Show notes for this episode: https://tim.blog/2025/09/03/dr-dominic-dagostino-all-things-ketones/For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textMost people don't realize it, but one of the simplest ways to understand your overall health is by tracking your blood sugar. In this eye-opening conversation, Dr. Boz, Annette Bosworth, MD and I dive into why blood glucose monitoring—and especially using a Continuous Glucose Monitor (CGM)—can give you a clear picture of how your body is functioning.From energy crashes to long-term chronic disease, blood sugar plays a bigger role in your health than you may think. And the best part? You don't need to be a scientist to make sense of it.We break it down in a way anyone can understand—engaging, thought-provoking, and sprinkled with a bit of humor—so you'll walk away with practical insights you can actually use. What You'll Learn in This Episode:Why insulin resistance is at the root of so many modern health struggles.How tracking your blood sugar (even with a simple monitor) can transform your health decisions.The surprising link between everyday choices and your long-term risk for chronic disease.Why CGMs aren't just for diabetics—they're a powerful tool for anyone serious about health.Simple, actionable tips to start taking control of your blood sugar today.  Time Stamps01:01 – Welcome to the 'Strong by Design' podcast! 02:21 – Meet today's special guest, Dr. Boz (Annette Bosworth, MD) 03:30 – What happened during the first days in Florida 07:33 – Finding better health in the 21st century 12:16 – Why knowing more about our bodies hasn't made us healthier 13:50 – Learn more about blood sugar and why it matters 18:15 – Know the real threshold for diabetes 21:15 – Why the insulin resistance problem is so hard 27:39 – The hidden reason behind “it's not working” 31:21 – Discover the role of muscle mass 34:54 – The healthy range for ketones revealed 38:45 – What Chris learned from fasting in the past 45:12 – Revisiting Dr. Boz's very first appearance 46:22 – Everything you need to know about CGM 51:34 – What healthy eating really looks like 56:55 – Foods that secretly spike your sugar 59:58 – Inside the 21-Day Metabolic Kick 1:06:43 – Why you might be having health issues 1:09:37 – Stay connected beyond the episode with Dr. Boz 1:14:00 – Please share and leave ratings & reviews for the SBD podcast! Resources:Dr Boz YouTube Channel Connect with Dr Boz:Instagram Connect with Chris:InstagramGrab your ACV Gummies, Buy One Get One FREE at CriticalBench.com, look for 'ACV Sale' in top right of page.Support the showConnect w/ CriticalBench: Youtube Facebook Instagram CriticalBench.com StrongByDesignPodcast.com

Have you ever caught yourself thinking that if you just had the right fitness tracker, the perfect app, or the latest gadget, your health and fitness goals would finally click into place?   I get it. Data feels safe. Numbers feel concrete. When everything about your body, health, fitness, and weight loss feels unpredictable, numbers might feel like a lifeline. But here's the truth: Your Oura ring won't get you to bed earlier. Your food tracking app won't put vegetables on your plate. And your CGM won't stop you from reaching for those M&Ms.   Tune in this week to learn about how you might be over-scientizing weight loss - a phenomenon I see repeatedly with clients who fill their homes with gadgets, but aren't using that information to guide or change their actions.    Get full show notes, transcript, and more information here: https://carriehollandmd.com/167

Send us a textFunctional nutritionist Kara Becker joins me on the podcast today to reframe PCOS and fertility through a metabolic lens (think blood sugar, inflammation, stress, and nervous system “safety,” not just sex hormones).In this episode, you'll learn:The 4 types of PCOS and why your type mattersHow blood sugar, cortisol, sleep, and stress intersect, and what your symptoms are trying to tell youKey labs to request and what “optimal” may look likeReal-life CGM takeaways Bio-individuality: tailoring nutrition and lifestyle to your bodyConnect with Kara:WebsiteInstagram Subscribe to the Aligned to Rise Podcast: Apple | SpotifyConnect w/ Alyssa: Instagram Website Work w/ Alyssa: Free Endo Diet Guide Work with me 1:1 Learn more about AlyssaDisclaimer: This podcast is for educational purposes only. This may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here.

Sarah, an anesthesiologist and mom of four, shares her family's adventures traveling the world while managing her 9-year-old son's type 1 diabetes. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Type 1 Diabetes Pro Tips - THE PODCAST Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * Omnipod Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

Did you know that brain fog can be a metabolic warning sign? In this episode, Dr. Austin Perlmutter breaks down how blood sugar swings, inflammation, and poor metabolic health silently chip away at your brain function over time. We also talk about how to eat to protect your mood, cognition, and long-term brain health, including the latest research on how to prevent dementia and Alzheimer's disease.Timestamps:[1:38] Intro[3:43] Conversation with Dr. Austin Perlmutter[10:27] You mentioned that inflammation can manifest in different ways, is there a reason it manifests a different way for one person than another?[17:53] What is excites you the most as far as the shifts we can make that result in better cognitive function?[29:34] Do you agree with Alzheimer's being called “type 3 diabetes”?[38:07] Are you recommending that people wear a CGM or that they get their metabolic markers tested regularly, and if so, what are those markers we should be looking at?[50:13] How can we improve brain fog after 40?[59:23] Do you think our screens and social media habits are changing  our brain function, and is there anything we can be doing nutritionally especially if we have to be on our computers all day for work?Episode Links:Dr. Austin Perlmutter's Website Follow Dr. Austin on InstagramBrain Wash: Detox Your Mind for Clearer Thinking, Deeper Relationships, and Lasting Happiness Big Bold HealthDr. Austin's YouTubeTop Causes of Brain FogBiomarkers:Hemoglobin A1cBasic metabolic panel (fasting insulin, fasting glucose)Lipid panel - Triglycerides are the key markerWaist to hip ratioSMASH fishSponsors:Go to https://thisisneeded.com/  and use coupon code WELLFED for 20% off your first order.Go to boncharge.com/WELLFED and use coupon code WELLFED to save 15% off any order.Go to http://mdlogichealth.com/whey-protein, and use coupon code WELLFED for 10% off.Go to wellminerals.us/creatine and use code WELLFED to get 10% off your order.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

Send us a textHello and welcome to the series “Stay in His Presence.” This is Episode 15 of Season 13, titled “Mary Magdalene”.We are celebrating five years of podcasting in 2025 by going into the archives and remastering the top episodes since June 20, 2020. . This is Stephanie, Wright. Thank you for joining us today. Let's get started He loved her so much that he died for her. And then He came back to life. She was the first one to bring the Good News of His resurrection to the world. Her name is Mary Magdalene. In this series, we are going to expound on truths and destroy myths about so-called bad girls of the Bible who were transformed into godly women memorialized in Holy Scripture.If you want to contact us or comment on this podcast, please visit our website and select www.cgmissions.com/podcasts, where all episodes are available by category in series format. You can see the most recent video and audio podcasts at: www.youtube.com/@cgmissionsinc then select from the video or podcast"Playlist." CGM is a 501(c)(3) nonprofit. Donations may be made on our website:https://www.cgmissions.com/donate-here-general-and-wecare/

In this encore episode, Andrea Donsky, a nutritionist with over 20 years of experience, menopause educator, published menopause researcher, and co-founder of WeAreMorphus, sits down with Dr. Sara Szal Gottfried, MD, to discuss Sara's personal experience with weight gain and how she uncovered the connection between diet, hormones, and weight loss in women, particularly during perimenopause and menopause.Topics Covered:Why keto diets often fail womenHow carbohydrates aren't the enemy, and why women in perimenopause and menopause need carbs, and which ones are best.How a continuous glucose monitor (CGM) can help you understand how your body responds to food and how this relates to insulin resistance and belly fat gain.Why calorie restriction fails in perimenopause and menopause.Dr. Gottfried's 4-week program.How to open detox pathways.How mindset can impact success in weight management and convey messages of hope.Links from the Podcast:Dr. Gottfried's Website: sarahgottfriedmd.comInstagram: @sarahgottfriedmdSend us a text ✅ Fill out our surveys: https://bit.ly/4jcVuLh

المصادر https://pmc.ncbi.nlm.nih.gov/articles/PMC3886333/ https://en.wikipedia.org/wiki/Mathematical_model https://www.matec-conferences.org/articles/matecconf/pdf/2019/41/matecconf_cscc2019_01063.pdf https://www.sciencedirect.com/science/article/abs/pii/S0010027719303270 https://pmc.ncbi.nlm.nih.gov/articles/PMC4830363/ https://news.mit.edu/2018/study-reveals-how-brain-tracks-objects-motion-0306 https://stories.uq.edu.au/the-brain/2022/timeline-of-brain-development/index.html https://makeagif.com/gif/ptolemys-model-of-the-universe-ci_cgM

Send us a textHello and welcome to “Stay in His Presence.” This is Episode 14, in Season 13.I'm your host, Stephanie Wright.We are celebrating five years of podcasting in 2025 by revisiting our archives and remastering the top ten episodes since June 20, 2020. Last time we were together, we went into the archives and retrieved Rahab Part 1, the top episode since we started podcasting. This time, we will continue with Rahab Part 2, another of the top ten episodes since 2020. There will be some updates to the podcast, so if you were with us in 2020, listen for a few changes and more words of inspiration.Thank you for joining us today as we revisit the series “Bad Girls, Gone Good: Rahab, Part 2.”Thank you for joining us today for the conclusion of our study on Rahab. Another "Bible Bad Girl Gone Good."Now stay tuned as Dr. Charles Wright closes us out with information on how you may contact us and access other podcasts.Until next time. If you want to contact us or comment on this podcast, please visit our website and select www.cgmissions.com/podcasts, where all episodes are available by category in series format. You can see the most recent video and audio podcasts at: www.youtube.com/@cgmissionsinc then select from the video or podcast"Playlist." CGM is a 501(c)(3) nonprofit. Donations may be made on our website:https://www.cgmissions.com/donate-here-general-and-wecare/

Marla, 44, shares 36 years with T1D, her late dive into pumping, her daughter's iron struggles, and her raw frustration with clueless doctors. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * Omnipod Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. 

If you want to get leaner and live longer, check out https://milliondollarbodylabs.com/   Have you ever felt guilty after eating a banana, or calculated how many snacks you could eat after a workout? I think we've all been there, struggling with food rules.   In this episode, I talked with Anna Vocino about food trauma and unlearning outdated food rules. We discussed how beliefs about fat from the 1990s and carb demonization from the 2000s still shape how we eat. People were taught low-fat foods were virtuous, and fruit was bad.   We also covered the issue of “gamifying” diets to allow for treats, which can lead to poor health outcomes even if weight is lost. True health requires considering both food quality and quantity. I learned that sustained change comes from addressing emotional patterns and beliefs, rather than relying on fear or self-hatred. Exercise is a separate component for well-being, not a reward system for eating certain foods.   Key Takeaways:   Outdated food rules, like fearing fat or demonizing carbs and fruit, are often based on marketing. Seeing exercise as a way to “earn” food or applying an “if it fits your macros” approach can be a form of disordered eating. Using tools like blood work and continuous glucose monitors (CGM) can provide insight into your body's unique responses to food.   Lasting health transformation stems from addressing underlying beliefs and cultivating self-love, not from fear or self-hatred. Resources: Anna Vocino is a cookbook author, co-host of the Fitness Confidential podcast and founder of Eat Happy Kitchen. https://eathappykitchen.com/   @annavocino (IG) https://instagram.com/annavocino  _________________________________________ Host Nate Palmer The founder of The Million Dollar Body and Author of "The Million Dollar Body Method", Nate has been in the industry of coaching over 15 years and has worked with over 1000 clients personally. Nate Palmer's Website: https://milliondollarbodylabs.com/    "The Million Dollar Body Method" by Nate Palmer: http://getnatesbook.com   Lean Energy Stack: https://milliondollarbodylabs.com/pages/lean   @_milliondollarbody (IG) https://www.instagram.com/_milliondollarbody  

This week on We Are T1D, things get chaotic — Jack nearly loses his foot to a digger, Mike sticks a dead sensor back on during a hypo, and the lads chat about CGMs, Type 2s, and oats. From dark humour to serious takeaways, it's one of the wildest episodes yet.What you'll hear in this episode:

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Maintaining a healthy waistline isn't just about aesthetics. Unwanted belly fat is also linked to a variety of heightened health risks. On today's show, you're going to learn the truth about belly fat – including what it is, how it differs from other body fat, and how to eliminate belly fat for good.  Today's guest, Ben Greenfield, is a New York Times bestselling author, speaker, and health consultant with an expertise in longevity. Ben's coaching programs have helped thousands of folks improve their body composition and optimize their overall health.  On today's show, Ben is back to demystify belly fat. He's sharing a specific formula for fat loss that you can integrate into your existing routine. We're also going to cover some controversial topics in the health and wellness space, including GLP-1 medications, fasting and cold therapy for women, and eliminating certain foods from your diet. I hope you enjoy this interview with the one and only Ben Greenfield!  In this episode you'll discover: What the MAHA movement is missing. (7:46) How to gain awareness of your caloric intake and movement levels. (8:47) What the Strike Stroll Shiver Strategy is. (9:43) The truth about fasting for women. (10:09) How long to exercise in the morning to lose body fat. (12:02)  The metabolic benefits of cold therapy. (13:19) Two specific foods to reduce for fat loss. (15:10) How to activate your body's GLP-1 naturally. (18:11) What to consider before using GLP-1 agonists. (19:36) How to measure glycemic variability. (26:54) The truth about how cold plunges affect cortisol levels in women. (34:18) What belly fat is comprised of. (42:21) The difference between white adipose tissue and brown adipose tissue. (42:38) Why discomfort is often an ingredient to improving your health. (46:39) A balanced approach to diet wars. (51:22) The best tools for recovery. (1:03:07) Items mentioned in this episode include: DrinkLMNT.com/model - Get a FREE sample pack of electrolytes with any order! Levels.link/model - Join today and get 2 free months with a one-year membership!  Boundless by Ben Greenfield - Read Ben's book!  Connect with Ben Greenfield Website / Facebook / Instagram Be sure you are subscribed to this podcast to automatically receive your episodes:  Apple Podcasts Spotify Soundcloud Pandora YouTube  This episode of The Model Health Show is brought to you by LMNT and Levels. Head to DrinkLMNT.com/model to claim a FREE sample pack of electrolytes with any purchase.  Learn how food affects your health with a continuous glucose monitor (CGM) from Levels. Join today at levels.link/model and get 2 free months with a one-year membership!

Nicole from Perth shares her 25-year type 1 diabetes journey — from pancreatitis at 13 to DKA, loss, GLP-1s, and thriving with CGM, Omnipod, and hard-won perspective. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Eversense CGM Medtronic Diabetes Tandem Mobi ** twiist AID System Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Stephen, 55, has lived with diabetes for 41 years and now drives innovation as the COO of a fast-moving startup in central PA. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! * Omnipod Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Among all paid Omnipod 5 G6G7 Pods Commercial and Medicare claims in 2024. Actual co-pay amount depends on patient's health plan and coverage, they may be higher or lower than the advertised amount. Source IQVIA OPC Library. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Most biohackers can fast for 72 hours or wear a CGM for fun. But ask them to make small talk at a barbecue? Complete system failure.  Because there's one crucial system many biohackers neglect to optimise: their social nervous system. We're going to sort that out today, with legendary journalist Jenny Valentish.  Check out Jenny's amazing new book (which I feature in) here The Introvert's Guide to Leaving the House: Solid advice for introverts, awkwards, sociophobes and stand-offishes Follow Jenny Valentish on Instagram.   THIS SHOW IS BROUGHT TO YOU BY: BiOptimizers Sleep Breakthrough and Magnesium Breakthrough These are BIOptimizers sleep and magnesium supplements which I take every night.  I have also been using the new Magnesium Breakthrough drink - delicious way to get magnesium. I have been putting a scoop in my protein shake after a workout.  Just go to BIOptimizers.com/tony and use code TONY15 for at least 15% off (often more). Code works worldwide, and on all their products.

Tracking your food doesn't have to be about weight loss. In this episode, Jess reframes tracking as a tool for awareness, not control, and shares different ways to reflect on what you're eating without counting calories. From food + mood journaling to using CGM data, you'll hear practical methods that help build intuition and confidence around food choices.If you're living with diabetes or prediabetes and want personalized support from a Registered Dietitian Nutritionist covered by insurance, visit diabetesdigital.co to connect with our culturally aware and weight-inclusive team. And if you love the show, don't forget to rate and review us on iTunes or Spotify—it makes a huge difference! For additional resources and show notes, head to diabetesdigital.co/podcast.

It's human nature to reduce and simplify complex situations. We like to think that weight loss is as simple as a formula like “calories in, calories out,” or that making better health choices is as easy as harnessing your willpower. The truth is that our bodies, minds, and behaviors are much more nuanced. And when it comes to our health, we often overlook the vital role that our environment and culture play. On this episode of The Model Health Show, you're going to hear my interview with Dr. Darshan Shah on the Extend Podcast. In this conversation, you're going to learn how your culture can influence your decisions and the fascinating science behind shared family meals. You'll also learn about the uptick in ultra-processed food consumption, why so many folks struggle to lose weight today, and my best tips for creating a family culture of health, connection, and unity. This conversation is full of important insights we can all apply, from making steps toward a more connected family culture, eating more whole foods, and cultivating better health in your home. So just click play and enjoy the show!    In this episode you'll discover:  How your environment influences your decisions. (12:20) The definition of culture. (13:00) Why our relationship with food is deeply intimate. (16:40) How the rates of processed food consumption have risen in recent decades. (20:50) Which food can reduce neuroinflammation. (25:51) The benefits of personalized nutrition. (30:47) A conversation on the FDA and red dye in the food supply. (32:49) How to create a healthy microculture within your home. (35:23) What post-ingestive feedback is. (49:41) A surprising connection between nutrient deficiencies, hunger, and obesity. (51:07) The problem with the idea of calories in, calories out. (56:10) How having a shared meal can benefit your physical and mental health. (1:04:35) Four tips to make family meals fun and engaging. (1:11:07) The minimum amount of times per week to share a meal with your children. (1:14:15)  Items mentioned in this episode include:  Levels.link/model - Join today and get 2 FREE months with a one-year membership!  DrinkLMNT.com/model - Get a FREE sample pack of electrolytes with any order! Eat Smarter Family Cookbook  - Transform the health, fitness, and connection of your entire family with the Eat Smarter Family Cookbook! Extend Podcast  - Listen to more of Dr. Darshan Shah's interviews!  Be sure you are subscribed to this podcast to automatically receive your episodes:   Apple Podcast Spotify Soundcloud Pandora YouTube   This episode of The Model Health Show is brought to you by Levels and LMNT. Learn how food affects your health with a continuous glucose monitor (CGM) from Levels. Join today at levels.link/model and get 2 free months with a one-year membership! Head to DrinkLMNT.com/model to claim a FREE sample pack of electrolytes with any purchase.